Compass Pathways reports positive Phase 3 trial results for COMP360 in depression

Compass Pathways plc (NASDAQ:CMPS) announced its Phase 3 COMP005 trial for COMP360, a synthetic psilocybin formulation, successfully met its primary endpoint in patients with treatment-resistant depression. A single 25 mg dose demonstrated a statistically significant reduction in symptom severity compared to placebo at week 6, with a mean treatment difference of -3.6 points on the MADRS scale (p<0.001). Safety data were consistent with prior studies, showing no new or unexpected issues, including no clinically meaningful imbalance in suicidality. The company intends to discuss these positive findings with the U.S. FDA, indicating significant progress towards potential regulatory approval for this novel therapeutic approach.

Analysis

Compass Pathways has reported a significant clinical development milestone, with its Phase 3 COMP005 trial for COMP360 psilocybin in treatment-resistant depression successfully meeting its primary endpoint. The single 25 mg dose demonstrated a statistically significant reduction in symptom severity at week 6, registering a mean treatment difference of -3.6 points on the MADRS scale compared to placebo, with a highly significant p-value of less than 0.001. This result represents a major de-risking event for the company's lead asset. Crucially, the safety profile remains favorable, as an independent Data Safety Monitoring Board review confirmed findings were consistent with previous studies and identified no new safety concerns or clinically meaningful imbalances in suicidality. While this initial data from the 258-participant COMP005 study is positive, the company's broader Phase 3 program includes the larger, ongoing COMP006 trial with up to 568 participants. Compass Pathways' immediate next step is to discuss these findings with the U.S. FDA, which will be a pivotal event for its regulatory pathway, though further data from the COMP006 trial is not anticipated until the second half of 2026.

Key Decisions for Investors

• The positive Phase 3 data significantly validates the clinical potential of COMP360, and investors should consider this a pivotal de-risking event for Compass Pathways' core asset.
• Attention should now shift to the company's upcoming discussions with the FDA, as the agency's feedback on this data will be the next major catalyst and will dictate the path to a potential new drug application.
• While the near-term outlook is strongly positive, investors must factor in the extended development timeline, with key data from the parallel and larger COMP006 trial not expected until H2 2026, indicating a multi-year path to potential commercialization.